Michael Hood, MD
Family Medicine · Newport, TNNPI 1053396432
Payments from drug & device makers
Across 811 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Medtronic$2K
- AbbVie$1K
- AstraZeneca$959
- GSK$931
- Johnson & Johnson$739
- plus $7K from 44 others
What the payments were for
- Travel & lodging$9697%
- Food & beverage$13,05892%
- Education$1431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,118
- FARXIGA$239
- SYMBICORT$239
- Ozempic$210
- BREZTRI AEROSPHERE$131
- INVOKANA$125
- XARELTO$125
- DUPIXENT$125
How this compares
$14,171 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 254 | $247,658 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 215 | $232,401 |
| OzempicSemaglutide | 156 | $196,507 |
| EliquisApixaban | 239 | $190,384 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 227 | $182,302 |
| MounjaroTirzepatide | 72 | $96,351 |
| TrulicityDulaglutide | 62 | $91,537 |
| RinvoqUpadacitinib | 11 | $71,105 |
| Repatha SureclickEvolocumab | 97 | $70,766 |
| XareltoRivaroxaban | 72 | $69,078 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $51,985 |
| FarxigaDapagliflozin Propanediol | 43 | $39,311 |
| LinzessLinaclotide | 65 | $38,150 |
| GlyxambiEmpagliflozin/Linagliptin | 25 | $28,742 |
| RybelsusSemaglutide | 25 | $25,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $673 | $317,969357 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $190 | $232,401215 claims |
| Novo NordiskOzempic, Rybelsus | $2,110 | $221,565181 claims |
| PfizerEliquis | $677 | $190,384239 claims |
| Lilly USA, LLCMounjaro, Trulicity | $304 | $187,888134 claims |
| GSKTrelegy Ellipta | $931 | $182,302227 claims |
| AbbVieRinvoq, Linzess, Vraylar | $1,029 | $129,02491 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere, Symbicort | $959 | $112,662170 claims |
| Johnson & JohnsonXarelto | $739 | $69,07872 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $23,41329 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $337 | $17,51726 claims |
| NovartisEntresto | $298 | $15,43813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Newport
- Kabir Harricharan SinghNewport$49K
- Catherine SpikerNewport$18K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.